Redefining the role(s) of endothelial αvβ3-integrin in angiogenesis

Biochemical Society Transactions

Volumn 42, Issue 6, 2014, Pages 1590-1595

  Atkinson, Samuel J ^a   Ellison, Tim S ^a   Steri, Veronica ^a   Gould, Emma ^a   Robinson, Stephen D ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Angiogenesis; Antagonist; Cancer; Endothelial cell; 3 integrin, tumour

Indexed keywords

VITRONECTIN RECEPTOR; INTEGRIN;

CANCER GROWTH; DRUG TARGETING; ENDOTHELIUM; HUMAN; IN VIVO STUDY; MOLECULAR BIOLOGY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TUMOR VASCULARIZATION; METABOLISM; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ENDOTHELIUM, VASCULAR; HUMANS; INTEGRINS;

EID: 84911872604     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20140206     Document Type: Review

References (53)

1. Brooks, P.C., Clark, R.A. and Cheresh, D.A. (1994) Requirement of vascular integrin αvβ3 for angiogenesis. Science 264, 569-571 CrossRef PubMed
2. Brooks, P.C., Montgomery, A.M., Rosenfeld, M., Reisfeld, R.A., Hu, T., Klier, G. and Cheresh, D.A. (1994) Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79, 1157-1164 CrossRef PubMed
3. Tucker, G.C. (2006) Integrins: molecular targets in cancer therapy. Curr. Oncol. Rep. 8, 96-103 CrossRef PubMed
4. Hodivala-Dilke, K.M., McHugh, K.P., Tsakiris, D.A., Rayburn, H., Crowley, D., Ullman-Culleré, M., Ross, F.P., Coller, B.S., Teitelbaum, S. and Hynes, R.O. (1999) β3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J. Clin. Invest. 103, 229-238 CrossRef PubMed
5. Reynolds, L.E., Wyder, L., Lively, J.C., Taverna, D., Robinson, S.D., Huang, X., Sheppard, D., Hynes, R.O. and Hodivala-Dilke, K.M. (2002) Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins. Nat. Med. 8, 27-34 CrossRef PubMed
6. Reynolds, A.R., Reynolds, L.E., Nagel, T.E., Lively, J.C., Robinson, S.D., Hicklin, D.J., Bodary, S.C. and Hodivala-Dilke, K.M. (2004) Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in β3-integrin-deficient mice. Cancer Res. 64, 8643-8650 CrossRef PubMed
7. Stupp, R. and Ruegg, C. (2007) Integrin inhibitors reaching the clinic. J. Clin. Oncol. 25, 1637-1638 CrossRef PubMed
8. Alghisi, G.C., Ponsonnet, L. and Ruegg, C. (2009) The integrin antagonist cilengitide activates αVβ3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS ONE 4, e4449 CrossRef PubMed
9. Reynolds, A.R., Hart, I.R., Watson, A.R., Welti, J.C., Silva, R.G., Robinson, S.D., Da Violante, G., Gourlaouen, M., Salih, M., Jones, M.C. et al. (2009) Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat. Med. 15, 392-400 CrossRef PubMed
10. Grogan, K. (2013), Merck KGaA's cilengitide fails in Phase III. PharmaTimes online (http://www.pharmatimes.com/article/13-02-26/Merck-KGaA-s-cilengitide-fails-in-Phase-III.aspx)
11. Hynes, R.O. (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110, 673-687 CrossRef PubMed
12. van der Flier, A., Badu-Nkansah, K., Whittaker, C.A., Crowley, D., Bronson, R.T., Lacy-Hulbert, A. and Hynes, R.O. (2010) Endothelial α5 and αv integrins cooperate in remodeling of the vasculature during development. Development 137, 2439-2449 CrossRef PubMed
13. Robinson, S.D. and Hodivala-Dilke, K.M. (2011) The role of β3-integrins in tumor angiogenesis: context is everything. Curr. Opin. Cell Biol. 23, 630-637 CrossRef PubMed
14. Brooks, P.C., Strömblad, S., Klemke, R., Visscher, D., Sarkar, F.H. and Cheresh, D.A. (1995) Antiintegrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96, 1815-1822 CrossRef PubMed
15. Cai, W. and Chen, X. (2006) Anti-angiogenic cancer therapy based on integrin αvβ3 antagonism. Anticancer Agents Med. Chem. 6, 407-428 CrossRef PubMed
16. Mahabeleshwar, G.H., Feng, W., Phillips, D.R. and Byzova, T.V. (2006) Integrin signaling is critical for pathological angiogenesis. J. Exp. Med. 203, 2495-2507 CrossRef PubMed
17. Feng, W., McCabe, N.P., Mahabeleshwar, G.H., Somanath, P.R., Phillips, D.R. and Byzova, T.V. (2008) The angiogenic response is dictated by β3 integrin on bone marrow-derived cells. J. Cell Biol. 183, 1145-1157 CrossRef PubMed
18. Watson, A.R., Pitchford, S.C., Reynolds, L.E., Direkze, N., Brittan, M., Alison, M.R., Rankin, S., Wright, N.A. and Hodivala-Dilke, K.M. (2010) Deficiency of bone marrow β3-integrin enhances non-functional neovascularization. J. Pathol. 220, 435-445 PubMed
19. Morgan, E.A., Schneider, J.G., Baroni, T.E., Uluçkan, O., Heller, E., Hurchla, M.A., Deng, H., Floyd, D., Berdy, A., Prior, J.L. et al. (2010) Dissection of platelet and myeloid cell defects by conditional targeting of the β3-integrin subunit. FASEB J. 24, 1117-1127 CrossRef PubMed
20. Steri, V., Ellison, T.S., Gontarczyk, A.M., Weilbaecher, K., Schneider, J.G., Edwards, D., Fruttiger, M., Hodivala-Dilke, K.M. and Robinson, S.D. (2014) Acute depletion of endothelial β3-integrin transiently inhibits tumor growth and angiogenesis in mice. Circ. Res. 114, 79-91 CrossRef PubMed
21. West, X.Z., Meller, N., Malinin, N.L., Deshmukh, L., Meller, J., Mahabeleshwar, G.H., Weber, M.E., Kerr, B.A., Vinogradova, O. and Byzova, T.V. (2012) Integrin β3 crosstalk with VEGFR accommodating tyrosine phosphorylation as a regulatory switch. PLoS ONE 7, e31071 CrossRef PubMed
22. 121. J. Biol. Chem. 276, 25520-25531 CrossRef PubMed
23. 165-receptor binding. J. Cell. Biochem. 85, 357-368 CrossRef PubMed
24. 407 phosphorylation. Mol. Biol. Cell 22, 2766-2776 CrossRef PubMed
25. Ballmer-Hofer, K., Andersson, A.E., Ratcliffe, L.E. and Berger, P. (2011) Neuropilin-1 promotes VEGFR-2 trafficking through Rab11 vesicles thereby specifying signal output. Blood 118, 816-826 CrossRef PubMed
26. Robinson, S.D., Reynolds, L.E., Kostourou, V., Reynolds, A.R., da Silva, R.G., Tavora, B., Baker, M., Marshall, J.F. and Hodivala-Dilke, K.M. (2009) αvβ3 integrin limits the contribution of neuropilin-1 to vascular endothelial growth factor-induced angiogenesis. J. Biol. Chem. 284, 33966-33981 CrossRef PubMed
27. Fantin, A., Herzog, B., Mahmoud, M., Yamaji, M., Plein, A., Denti, L., Ruhrberg, C. and Zachary, I. (2014) Neuropilin 1 (NRP1) hypomorphism combined with defective VEGF-A binding reveals novel roles for NRP1 in developmental and pathological angiogenesis. Development 141, 556-562 CrossRef PubMed
28. Seerapu, H.R., Borthakur, S., Kong, N., Agrawal, S., Drazba, J., Vasanji, A., Fantin, A., Ruhrberg, C., Buck, M. and Horowitz, A. (2013) The cytoplasmic domain of neuropilin-1 regulates focal adhesion turnover. FEBS Lett. 587, 3392-3399 CrossRef PubMed
29. Raimondi, C., Fantin, A., Lampropoulou, A., Denti, L., Chikh, A. and Ruhrberg, C. (2014) Imatinib inhibits VEGF-independent angiogenesis by targeting neuropilin 1-dependent ABL1 activation in endothelial cells. J. Exp. Med. 211, 1167-1183 CrossRef PubMed
30. Valdembri, D., Caswell, P.T., Anderson, K.I., Schwarz, J.P., König, I., Astanina, E., Caccavari, F., Norman, J.C., Humphries, M.J., Bussolino, F. and Serini, G. (2009) Neuropilin-1/GIPC1 signaling regulates α5β1 integrin traffic and function in endothelial cells. PLoS Biol. 7, e25 CrossRef PubMed
31. Schiller, H.B., Friedel, C.C., Boulegue, C. and Fassler, R. (2011) Quantitative proteomics of the integrin adhesome show a myosin II-dependent recruitment of LIM domain proteins. EMBO Rep. 12, 259-266 CrossRef PubMed
32. Schiller, H.B., Hermann, M.R., Polleux, J., Vignaud, T., Zanivan, S., Friedel, C.C., Sun, Z., Raducanu, A., Gottschalk, K.E., Théry, M. et al. (2013) β1-and αv-class integrins cooperate to regulate myosin II during rigidity sensing of fibronectin-based microenvironments. Nat. Cell Biol. 15, 625-636 CrossRef PubMed
33. Mulgrew, K., Kinneer, K., Yao, X.T., Ward, B.K., Damschroder, M.M., Walsh, B., Mao, S.Y., Gao, C., Kiener, P.A., Coats, S. et al. (2006) Direct targeting of αvβ3 integrin on tumor cells with a monoclonal antibody, abegrin. Mol. Cancer Ther. 5, 3122-3129 CrossRef PubMed
34. Teti, A., Migliaccio, S. and Baron, R. (2002) The role of the αVβ3 integrin in the development of osteolytic bone metastases: a pharmacological target for alternative therapy? Calcif. Tissue Int. 71, 293-299 CrossRef
35. Burkhart, D.J., Kalet, B.T., Coleman, M.P., Post, G.C. and Koch, T.H. (2004) Doxorubicin-formaldehyde conjugates targeting αvβ3 integrin. Mol. Cancer Ther. 3, 1593-1604 PubMed
36. Cao, Q., Li, Z.B., Chen, K., Wu, Z., He, L., Neamati, N. and Chen, X. (2008) Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer. Eur. J. Nucl. Med. Mol. Imaging 35, 1489-1498 CrossRef PubMed
37. Chen, K. and Chen, X. (2011) Integrin targeted delivery of chemotherapeutics. Theranostics 1, 189-200 CrossRef PubMed
38. Chen, H., Zhen, Z., Tang, W., Todd, T., Chuang, Y.J., Wang, L., Pan, Z. and Xie, J. (2013) Label-free luminescent mesoporous silica nanoparticles for imaging and drug delivery. Theranostics 3, 650-657 CrossRef PubMed
39. Wang, K., Zhang, X., Liu, Y., Liu, C., Jiang, B. and Jiang, Y. (2014) Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates. Biomaterials 35, 8735-8747 CrossRef PubMed
40. Janssen, M.L., Oyen, W.J., Dijkgraaf, I., Massuger, L.F., Frielink, C., Edwards, D.S., Rajopadhye, M., Boonstra, H., Corstens, F.H. and Boerman, O.C. (2002) Tumor targeting with radiolabeled αvβ3 integrin binding peptides in a nude mouse model. Cancer Res. 62, 6146-6151 PubMed
41. Liu, Z., Wang, F. and Chen, X. (2008) Integrin αvβ3-targeted cancer therapy. Drug Dev. Res. 69, 329-339 CrossRef PubMed
42. Veeravagu, A., Liu, Z., Niu, G., Chen, K., Jia, B., Cai, W., Jin, C., Hsu, A.R., Connolly, A.J., Tse, V. et al. (2008) Integrin αvβ3-targeted radioimmunotherapy of glioblastoma multiforme. Clin. Cancer Res. 14, 7330-7339 CrossRef PubMed
43. van Horssen, R., Ten Hagen, T.L. and Eggermont, A.M. (2006) TNF-α in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11, 397-408 CrossRef PubMed
44. Wang, H., Chen, K., Cai, W., Li, Z., He, L., Kashefi, A. and Chen, X. (2008) Integrin-targeted imaging and therapy with RGD4C-TNF fusion protein. Mol. Cancer Ther. 7, 1044-1053 CrossRef PubMed
45. Mingozzi, M., Manzoni, L., Arosio, D., Dal Corso, A., Manzotti, M., Innamorati, F., Pignataro, L., Lecis, D., Delia, D., Seneci, P. and Gennari, C. (2014) Synthesis and biological evaluation of dual action cyclo-RGD/SMAC mimetic conjugates targeting αvβ3/αvβ5 integrins and IAP proteins. Org. Biomol. Chem. 12, 3288-3302 CrossRef PubMed
46. Sakurai, Y., Hatakeyama, H., Sato, Y., Hyodo, M., Akita, H., Ohga, N., Hida, K. and Harashima, H. (2014) RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system. J. Control. Release 173, 110-118 CrossRef PubMed
47. 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy. J Nucl. Med. 50, 116-122 CrossRef PubMed
48. 64Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors. Nucl. Med. Biol. 41, 133-139 CrossRef PubMed
49. Danhier, F., Le Breton, A. and Préat, V. (2012) RGD-based strategies to target αvβ3 integrin in cancer therapy and diagnosis. Mol. Pharm. 9, 2961-2973 CrossRef PubMed
50. Bouzin, C. and Feron, O. (2007) Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery. Drug Resist. Updat. 10, 109-120 CrossRef PubMed
51. Switala-Jelen, K., Dabrowska, K., Opolski, A., Lipinska, L., Nowaczyk, M. and Gorski, A. (2004) The biological functions of β3 integrins. Folia Biol. 50, 143-152 PubMed
52. Smith, J.W. (2003) Cilengitide Merck. Curr. Opin. Invest. Drugs 4, 741-745 PubMed
53. Ghitti, M., Spitaleri, A., Valentinis, B., Mari, S., Asperti, C., Traversari, C., Rizzardi, G.P. and Musco, G. (2012) Molecular dynamics reveal that isoDGR-containing cyclopeptides are true αvβ3 antagonists unable to promote integrin allostery and activation. Angew. Chem. Int. Ed. Engl. 51, 7702-7705 CrossRef PubMed